Pacira BioSciences (PCRX) faces Exparel generic threats in 2024. Learn about risks, portfolio strategy shifts, and key ...
Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs). The FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback